Skip to main content


Log in

Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript



Lung cancer in never smokers presents predominately as adenocarcinoma and in females. MicroRNA-183 (miR-183) has various expression patterns in types of human cancers. In the present study, we evaluated the expression of miR-183-3p in female lung adenocarcinoma and adjacent noncancerous tissues and explored its relationship with clinicopathological characteristics and prognosis.


In the present study, a hundred female nonsmoking patients who were newly diagnosed and histologically confirmed as lung adenocarcinoma at Tianjin Medical University Cancer Hospital were included. miR-183-3p expression of surgically removed NSCLC tissues and their corresponding normal lung tissues was measured by qRT-PCR assay. Associations of miR-183-3p expression with clinicopathological features were determined using the Student’s t test. Log-rank test, and Cox proportional hazards model were used for survival analysis.


At first, miR-183-3p was up-regulated in lung cancer tissues when compared with the corresponding noncancerous lung tissues. Moreover, the expression of miR-183-3p in tumor tissue was found to be associated with lymph node metastasis (P = 0.043), clinical stage (P = 0.015), and EGFR mutation (P = 0.003). At last, high miR-183-3p expression was also associated with both poor overall survival and progression-free survival of women with lung adenocarcinoma (P = 0.005 and P = 0.010, respectively).


This study suggested that miR-183-3p expression might be involved in lung cancer pathogenesis and progression, and could be used as a potential prognostic biomarker of female lung adenocarcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others


  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  2. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. Esti-mates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  PubMed  CAS  Google Scholar 

  3. Sun S, Schiller JH, Gazdar AF. Lung cancer in never smokers—a different disease. Nat Rev Cancer. 2007;7:778–90.

    Article  PubMed  CAS  Google Scholar 

  4. Yano T, Miura N, Takenaka T, Haro A, Okazaki H, Ohba T, et al. Never-smoking nonsmall cell lung cancer as a separate entity. Cancer. 2008;113:1012–8.

    Article  PubMed  Google Scholar 

  5. Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity. J Clin Oncol. 2006;24:2245–51.

    Article  PubMed  Google Scholar 

  6. Esquela-Kerscher ASF. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.

    Article  PubMed  CAS  Google Scholar 

  7. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6:857–66.

    Article  PubMed  CAS  Google Scholar 

  8. Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. PLoS One. 2013;8:e81408.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 2011;11:393.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Mei Q, Li X, Meng Y, Wu Z, Guo M, Zhao Y, et al. A facile and specific assay for quantifying microRNA by an optimized RT-qPCR approach. PLoS One. 2012;7:e46890.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, et al. Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 2013;30:681.

    Article  PubMed  CAS  Google Scholar 

  12. Võsa U, Vooder T, Kolde R, Fischer K, Välk K, Tõnisson N, et al. Identification of miR-374a as a prognostic marker for survival in patients with early-stage nonsmall cell lung cancer. Genes Chromosom Cancer. 2011;50:812–22.

    Article  PubMed  Google Scholar 

  13. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res. 2010;70:367–77.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Chen L, Li Y, Fu Y, Peng J, Mo MH, Stamatakos M, et al. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. PLoS One. 2013;8:e54213.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  15. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6:e18286.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010;126:1166–76.

    PubMed  CAS  Google Scholar 

  18. Zheng WW, Huang CM, Xie JW, Zheng CH, Li P, Wang JB, et al. Expression of microRNA-183 in stage II (gastric cancer and its association with Ezrin protein. Zhonghua Wei Chang Wai Ke Za Zhi. 2012;15:723–6.

    PubMed  Google Scholar 

  19. Li J, Liang S, Jin H, Xu C, Ma D. X. L. Tiam1, negatively regulated by miR-22, miR-183 andmiR-31, is involved in migration, invasion and viability of ovarian cancer cells. Oncol Rep. 2012;27:1835–42.

    PubMed  CAS  Google Scholar 

  20. Mian C, Pennelli G, Fassan M, Balistreri M, Barollo S, Cavedon E, et al. MicroRNA profiles in familial and sporadic medullary thyroid carcinoma: preliminary relationships with RET status and outcome. Thyroid. 2012;22:890–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102:522–9.

    Article  PubMed  CAS  Google Scholar 

  22. Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, et al. Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012;180:2440–51.

    Article  PubMed  CAS  Google Scholar 

  23. Xie L, Ushmorov A, Leithäuser F, Guan HSC, Färbinger J, Pelzer C, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;195:3503–11.

    Article  Google Scholar 

  24. Tang H, Bian Y, Tu C, Wang Z, Yu Z, Liu Q, et al. The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 2013;13:221–31.

    Article  PubMed  CAS  Google Scholar 

  25. Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai ZL, et al. microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108:1659–67.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer. 2010;10:502.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett. 2008;582:3663–8.

    Article  PubMed  CAS  Google Scholar 

  28. Sarver AL, Li L. S. S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010;70:9570–80.

    Article  PubMed  CAS  Google Scholar 

  29. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell. 2008;133:403–14.

    Article  PubMed  CAS  Google Scholar 

  30. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol. 2011;226:2762–81.

    Article  PubMed  CAS  Google Scholar 

Download references


Research support: this study was supported by National Natural Science Foundation of China (No. 81372229) and Natural Science Foundation of Tianjin (No. 13JCYBJC23100).

Conflict of interest

The authors declared that they have no conflicts of interest to this work.

Author information

Authors and Affiliations


Corresponding author

Correspondence to B. Qian.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, F., Zhang, H., Su, Y. et al. Up-regulation of microRNA-183-3p is a potent prognostic marker for lung adenocarcinoma of female non-smokers. Clin Transl Oncol 16, 980–985 (2014).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: